Discover and read the best of Twitter Threads about #ACC19
Most recents (5)
As @DrMarthaGulati destroys her competition today at #ACC19 , there really is no worthy debate on whether a physician should participate in #SoMe or not.
A thread on where physicians need to obtain #SoMe skills and lead...
A thread on where physicians need to obtain #SoMe skills and lead...
The principles of advocacy.
Op-ed piece by Dr. LeeAnne Luft:
ncbi.nlm.nih.gov/pmc/articles/P…
Call to action by Dr. Angira Patel @sciam blogs.scientificamerican.com/observations/i…
Eye-opening @ETSshow podcast w/ @PeterHotez explorethespaceshow.com/podcasting/pet…
Op-ed piece by Dr. LeeAnne Luft:
ncbi.nlm.nih.gov/pmc/articles/P…
Call to action by Dr. Angira Patel @sciam blogs.scientificamerican.com/observations/i…
Eye-opening @ETSshow podcast w/ @PeterHotez explorethespaceshow.com/podcasting/pet…
Novel uses of #SoMe & documentation of impact.
#Tweetorials perspective by @Doctor_V 33charts.com/tweetorial/
Article on Physician exemplars ( incl. @EricTopol @SeattleMamaDoc )
patientpop.com/blog/marketing…
#SoMe portfolios for academics jgme.org/doi/full/10.43…
#Tweetorials perspective by @Doctor_V 33charts.com/tweetorial/
Article on Physician exemplars ( incl. @EricTopol @SeattleMamaDoc )
patientpop.com/blog/marketing…
#SoMe portfolios for academics jgme.org/doi/full/10.43…
Do you use #whyCMR in your patients undergoing #TAVR. More slides in the thread #CVimaging #ACCImaging #ACC19 
Annular assessment by #whyCMR accuracy similar to #YesCCT
data from @JACCJournals
#ACCimaging #ACC19 #Cvimaging
data from @JACCJournals
#ACCimaging #ACC19 #Cvimaging
#ACC19 #LBCT
@PCRonline
1PANACHE: Safety:Efficacy of Neladenoson Bialanate, Partial Adenosine A1 Receptor Agonist, in CHF & Preserved EF: PANACHE RCT
2PIONEER-HF: Initiation of Angiotensin-Neprilysin Inhibition after Acute Decomp CHF: Open-Label Extension of
PIONEER-HF Trial
@PCRonline
1PANACHE: Safety:Efficacy of Neladenoson Bialanate, Partial Adenosine A1 Receptor Agonist, in CHF & Preserved EF: PANACHE RCT
2PIONEER-HF: Initiation of Angiotensin-Neprilysin Inhibition after Acute Decomp CHF: Open-Label Extension of
PIONEER-HF Trial
3 Hopeful Heart Trial: Blended Collaborative Care for Treating ❤️Failure & Comorbid Depression: 12-Month Outcomes
4 CODIACS-QoL: Randomized Trial of Depression Screening After ACS: Comparison of Depression Identification After ACS-QOL & Cost Effectiveness
4 CODIACS-QoL: Randomized Trial of Depression Screening After ACS: Comparison of Depression Identification After ACS-QOL & Cost Effectiveness
The countdown to #ACC19 has begun!
Here’s a THREAD about the much anticipated #AppleHeartStudy
(results to be presented at 9am THIS Saturday, March 17 at #ACC19 by #EPeeps Mintu Turakhia AKA @leftbundle from @SCCR_Stanford!)
#ACCEP
Here’s a THREAD about the much anticipated #AppleHeartStudy
(results to be presented at 9am THIS Saturday, March 17 at #ACC19 by #EPeeps Mintu Turakhia AKA @leftbundle from @SCCR_Stanford!)
#ACCEP
The #AppleHeartStudy aimed to test the ability of a smartwatch algorithm to detect an irregular pulse consistent with AF, & to estimate its diagnostic yield in a large population:
#ACC19 #ACCEP
#ACC19 #ACCEP
The cool thing about the #AppleHeartStudy, is that all of it was done virtually. ALL. OF. IT. Enrollment, consent, study visits, patch monitoring. Here are the #AppleHeartStudy ‘s main objectives in detail:
#ACC19 #ACCEP
#ACC19 #ACCEP
Two noteworthy findings by Wang @rkwadhera @DLBHATTMD in @JAMACardio:
1) Hospitals in the @usnews top 50 have better mortality rates than other hospitals in AMI, CABG & HF. Better HCAHPS, too. Not too surprising, but certainly reassuring.
2) But...
jamanetwork.com/journals/jamac…
1/
1) Hospitals in the @usnews top 50 have better mortality rates than other hospitals in AMI, CABG & HF. Better HCAHPS, too. Not too surprising, but certainly reassuring.
2) But...
jamanetwork.com/journals/jamac…
1/
2) But those same top hospitals do no better than others on readmission.
Why? Well, we have to ask ourselves whether readmission is a valid indicator of quality. And if it is, is it valid in all patient cohorts, or only certain ones?
2/
Why? Well, we have to ask ourselves whether readmission is a valid indicator of quality. And if it is, is it valid in all patient cohorts, or only certain ones?
2/
As Wang @rkwadhera @DLBHATTMD understatedly write:
“The observed discrepancy between readmissions and other performance measures raises concern that readmissions may not be an adequate metric of hospital care quality.”
3/
“The observed discrepancy between readmissions and other performance measures raises concern that readmissions may not be an adequate metric of hospital care quality.”
3/
